Publicacións nas que colabora con María Rodríguez Remírez (17)

2021

  1. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

    Biomedicine and Pharmacotherapy, Vol. 144

2020

  1. Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study

    Neuroendocrinology, Vol. 110, Núm. 1-2, pp. 50-62

  2. Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas

    Neuroendocrinology, Vol. 111, Núm. 1-2, pp. 146-157

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer

    Journal of Geriatric Oncology, Vol. 10, Núm. 5, pp. 742-748

  4. UNR/CSDE1 expression is critical to maintain invasive phenotype of colorectal cancer through regulation of c-MYC and epithelial-to-mesenchymal transition

    Journal of Clinical Medicine, Vol. 8, Núm. 4

2018

  1. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

  2. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept

    PLoS ONE, Vol. 12, Núm. 8

2016

  1. Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy

    Pathology Research and Practice, Vol. 212, Núm. 12, pp. 1133-1137

  2. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer

    Journal of Cellular and Molecular Medicine, Vol. 20, Núm. 9, pp. 1729-1736

  3. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: A retrospective observational cohort study

    BMC Cancer, Vol. 16, Núm. 1

  4. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer

    Oncotarget, Vol. 7, Núm. 30, pp. 47954-47965

2015

  1. Identification of Poor-outcome Biliopancreatic Carcinoma Patients with Two-marker Signature Based on ATF6α and p-p38 "sTARD Compliant"

    Medicine (United States), Vol. 94, Núm. 45, pp. e1972

2014

  1. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

    British Journal of Cancer, Vol. 110, Núm. 11, pp. 2700-2707

  2. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1